Fall Semester 2026–2027 Advanced Pharmacology
Updated 2026 | 190+ Questions and Answers |
Advanced Pharmacology Comprehensive Study Guide,
Practice Exam, Exam Prep Test Bank,
Pharmacokinetics, Pharmacodynamics, Drug
Classifications, Medication Safety, Adverse Drug
Reactions, Clinical Therapeutics, Dosage Calculations,
Patient Education, Clinical Judgment, Next Generation
NCLEX (NGN), Detailed Rationales and Complete
Revision Material
Question 1: A 68-year-old male with a history of heart failure with reduced
ejection fraction (HFrEF) is initiated on sacubitril/valsartan. Which of the
following best describes the primary mechanism by which this combination
therapy provides its therapeutic benefit?
A. Inhibition of aldosterone synthesis and direct renin antagonism
B. Selective blockade of the angiotensin II type 1 receptor and inhibition of neprilysin,
preventing the breakdown of natriuretic peptides
C. Dual inhibition of angiotensin-converting enzyme and the angiotensin II type 2
receptor
D. Competitive antagonism of mineralocorticoid receptors and increased renal excretion
of sodium
CORRECT ANSWER: B. Selective blockade of the angiotensin II type 1 receptor
and inhibition of neprilysin, preventing the breakdown of natriuretic peptides
Rationale: Sacubitril/valsartan is a first-in-class combination drug. Valsartan is an
angiotensin II receptor blocker (ARB) that selectively blocks the AT1 receptor. Sacubitril
is a neprilysin inhibitor, which prevents the breakdown of endogenous natriuretic
peptides, leading to vasodilation, increased natriuresis, and reduced sympathetic tone.
This dual action is beneficial in HFrEF and has been shown to reduce mortality
compared to enalapril.
Question 2: A patient with type 2 diabetes mellitus and chronic kidney disease
(eGFR 35 mL/min/1.73m²) is started on a medication that inhibits the sodium-
glucose cotransporter 2 (SGLT2). Which of the following adverse effects is
most specific to this pharmacologic class and requires immediate patient
education?
A. Hyperkalemia and metabolic acidosis
B. Euglycemic diabetic ketoacidosis (DKA) and genital mycotic infections
C. Acute pancreatitis and severe hypoglycemia
D. Peripheral neuropathy and weight gain
CORRECT ANSWER: B. Euglycemic diabetic ketoacidosis (DKA) and genital
mycotic infections
,Rationale: SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin) increase
urinary glucose excretion. This creates a glycemic environment conducive to fungal
overgrowth, leading to an increased risk of genital mycotic infections (e.g., Candida
balanitis, vulvovaginitis). Additionally, these agents can promote ketogenesis and reduce
insulin secretion, which can precipitate euglycemic DKA (DKA with blood glucose levels
< 250 mg/dL), especially in the setting of illness, dehydration, or reduced insulin doses.
Question 3: A 75-year-old woman with severe, refractory osteoporosis is
prescribed teriparatide. What is the fundamental mechanism of action of this
anabolic agent?
A. Inhibition of osteoclast activity by binding to the RANK receptor
B. Non-selective inhibition of cyclooxygenase-1 and -2 enzymes
C. Selective estrogen receptor modulation in bone tissue
D. Intermittent administration of parathyroid hormone (PTH) analog that stimulates
osteoblastic activity and bone formation
CORRECT ANSWER: D. Intermittent administration of parathyroid hormone
(PTH) analog that stimulates osteoblastic activity and bone formation
Rationale: Teriparatide is a recombinant human parathyroid hormone (PTH 1-34). In
contrast to continuous PTH elevation (which causes bone resorption), intermittent
administration paradoxically stimulates osteoblasts, increasing bone mineral density and
improving bone microarchitecture. It is the only anabolic agent for osteoporosis,
promoting new bone formation rather than just preventing resorption.
Question 4: A patient on long-term, high-dose glucocorticoid therapy is
prescribed a bisphosphonate for osteoporosis prevention. What is the primary
mechanism by which bisphosphonates exert their anti-resorptive effects?
A. Stimulation of osteoblast differentiation through the Wnt/β-catenin pathway
B. Binding to hydroxyapatite and inducing osteoclast apoptosis via inhibition of farnesyl
pyrophosphate synthase
C. Direct antagonism of parathyroid hormone receptors on osteoclasts
D. Conversion to active metabolites that inhibit osteocyte apoptosis
CORRECT ANSWER: B. Binding to hydroxyapatite and inducing osteoclast
apoptosis via inhibition of farnesyl pyrophosphate synthase
Rationale: Bisphosphonates are pyrophosphate analogs that bind avidly to bone mineral
(hydroxyapatite). They are internalized by osteoclasts during bone resorption. Once
inside, they inhibit farnesyl pyrophosphate synthase, an enzyme in the mevalonate
pathway. This prevents the prenylation of essential proteins, leading to osteoclast
dysfunction and apoptosis, thereby reducing bone resorption.
Question 5: Which of the following characteristics is a significant advantage of
the third-generation antiseizure medication lacosamide compared to
traditional sodium channel blockers?
,A. It has a significantly longer half-life allowing for once-weekly dosing
B. It acts by a novel mechanism that does not involve the sodium channel, making it
effective against all seizure types
C. It has a selective and slow inactivation of voltage-gated sodium channels with
minimal effect on fast inactivation, potentially leading to a better side-effect profile
D. It is exclusively metabolized by the kidneys, making it safe in all patients with hepatic
impairment
CORRECT ANSWER: C. It has a selective and slow inactivation of voltage-gated
sodium channels with minimal effect on fast inactivation, potentially leading
to a better side-effect profile
Rationale: Lacosamide enhances the slow inactivation of voltage-gated sodium
channels, with little to no effect on the fast inactivation process. This is in contrast to
drugs like phenytoin or carbamazepine, which primarily affect fast inactivation. The
selective action on slow inactivation is thought to be responsible for its efficacy and a
potentially more favorable central nervous system side-effect profile, such as less
cognitive impairment.
Question 6: A patient with a history of gout is prescribed hydrochlorothiazide
for hypertension. The patient's serum uric acid level increases. This adverse
effect is primarily due to which action of thiazide diuretics?
A. Increased urate reabsorption in the proximal convoluted tubule
B. Competitive inhibition of urate secretion by the organic anion transporter (OAT) in the
proximal tubule
C. Inhibition of uric acid synthesis by xanthine oxidase
D. Enhanced degradation of purines leading to increased uric acid production
CORRECT ANSWER: B. Competitive inhibition of urate secretion by the organic
anion transporter (OAT) in the proximal tubule
Rationale: Thiazide diuretics decrease the excretion of uric acid. They are weak organic
acids that compete with urate for secretion via the organic anion transporter (OAT) in
the proximal convoluted tubule. This reduces uric acid clearance, leading to elevated
serum uric acid levels and potentially precipitating gout in susceptible patients.
Question 7: A 52-year-old female is started on anastrozole for estrogen
receptor-positive breast cancer. What is the precise pharmacologic target and
effect of this medication?
A. Irreversible inhibition of the estrogen receptor on breast tissue
B. Competitive inhibition of 17β-hydroxysteroid dehydrogenase
C. Selective antagonism of the progesterone receptor
D. Reversible inhibition of the aromatase enzyme, decreasing peripheral conversion of
androgens to estrogens
CORRECT ANSWER: D. Reversible inhibition of the aromatase enzyme,
decreasing peripheral conversion of androgens to estrogens
, Rationale: Anastrozole is a non-steroidal aromatase inhibitor. Aromatase is the enzyme
responsible for the conversion of androstenedione and testosterone to estrone and
estradiol, respectively. By reversibly inhibiting this enzyme, it reduces circulating
estrogen levels, a key driver for hormone-responsive breast cancer growth in
postmenopausal women.
Question 8: A patient with severe peptic ulcer disease related to NSAID use is
prescribed misoprostol. Which of the following is the most critical
contraindication to this medication, and what is the primary mechanism for its
gastroprotective effect?
A. Pregnancy; it stimulates uterine contractions and increases gastric mucus and
bicarbonate secretion
B. Asthma; it inhibits prostaglandin synthesis
C. Renal failure; it causes significant sodium retention
D. Hypertension; it acts as a potent vasoconstrictor
CORRECT ANSWER: A. Pregnancy; it stimulates uterine contractions and
increases gastric mucus and bicarbonate secretion
Rationale: Misoprostol is a synthetic prostaglandin E1 analog. Its primary mechanism of
gastroprotection is stimulating the production of gastric mucus and bicarbonate, thereby
enhancing the mucosal barrier. It also reduces acid secretion. Misoprostol is absolutely
contraindicated in pregnancy because it is a potent abortifacient and can cause uterine
contractions and cervical ripening.
Question 9: A 48-year-old male with bipolar disorder is started on lithium.
Which of the following is the primary and most widely accepted mechanism of
action for lithium's mood-stabilizing effects?
A. Blockade of dopamine D2 receptors in the mesolimbic pathway
B. Enhancement of GABA-A receptor activity throughout the central nervous system
C. Inhibition of the sodium-potassium-ATPase pump and alteration of neurotransmitter
reuptake
D. Inhibition of inositol monophosphatase, leading to depletion of inositol and disruption
of the phosphatidylinositol second messenger system
CORRECT ANSWER: D. Inhibition of inositol monophosphatase, leading to
depletion of inositol and disruption of the phosphatidylinositol second
messenger system
Rationale: While the exact mechanism of lithium is not fully understood, a prominent
theory involves its inhibition of inositol monophosphatase. This enzyme is crucial for the
recycling of inositol in the phosphatidylinositol (PI) cycle. Inhibition leads to a depletion
of inositol, which disrupts the signaling pathways that depend on this second messenger
system, particularly in neurons. This is thought to affect intracellular signaling pathways
that modulate mood.
Updated 2026 | 190+ Questions and Answers |
Advanced Pharmacology Comprehensive Study Guide,
Practice Exam, Exam Prep Test Bank,
Pharmacokinetics, Pharmacodynamics, Drug
Classifications, Medication Safety, Adverse Drug
Reactions, Clinical Therapeutics, Dosage Calculations,
Patient Education, Clinical Judgment, Next Generation
NCLEX (NGN), Detailed Rationales and Complete
Revision Material
Question 1: A 68-year-old male with a history of heart failure with reduced
ejection fraction (HFrEF) is initiated on sacubitril/valsartan. Which of the
following best describes the primary mechanism by which this combination
therapy provides its therapeutic benefit?
A. Inhibition of aldosterone synthesis and direct renin antagonism
B. Selective blockade of the angiotensin II type 1 receptor and inhibition of neprilysin,
preventing the breakdown of natriuretic peptides
C. Dual inhibition of angiotensin-converting enzyme and the angiotensin II type 2
receptor
D. Competitive antagonism of mineralocorticoid receptors and increased renal excretion
of sodium
CORRECT ANSWER: B. Selective blockade of the angiotensin II type 1 receptor
and inhibition of neprilysin, preventing the breakdown of natriuretic peptides
Rationale: Sacubitril/valsartan is a first-in-class combination drug. Valsartan is an
angiotensin II receptor blocker (ARB) that selectively blocks the AT1 receptor. Sacubitril
is a neprilysin inhibitor, which prevents the breakdown of endogenous natriuretic
peptides, leading to vasodilation, increased natriuresis, and reduced sympathetic tone.
This dual action is beneficial in HFrEF and has been shown to reduce mortality
compared to enalapril.
Question 2: A patient with type 2 diabetes mellitus and chronic kidney disease
(eGFR 35 mL/min/1.73m²) is started on a medication that inhibits the sodium-
glucose cotransporter 2 (SGLT2). Which of the following adverse effects is
most specific to this pharmacologic class and requires immediate patient
education?
A. Hyperkalemia and metabolic acidosis
B. Euglycemic diabetic ketoacidosis (DKA) and genital mycotic infections
C. Acute pancreatitis and severe hypoglycemia
D. Peripheral neuropathy and weight gain
CORRECT ANSWER: B. Euglycemic diabetic ketoacidosis (DKA) and genital
mycotic infections
,Rationale: SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin) increase
urinary glucose excretion. This creates a glycemic environment conducive to fungal
overgrowth, leading to an increased risk of genital mycotic infections (e.g., Candida
balanitis, vulvovaginitis). Additionally, these agents can promote ketogenesis and reduce
insulin secretion, which can precipitate euglycemic DKA (DKA with blood glucose levels
< 250 mg/dL), especially in the setting of illness, dehydration, or reduced insulin doses.
Question 3: A 75-year-old woman with severe, refractory osteoporosis is
prescribed teriparatide. What is the fundamental mechanism of action of this
anabolic agent?
A. Inhibition of osteoclast activity by binding to the RANK receptor
B. Non-selective inhibition of cyclooxygenase-1 and -2 enzymes
C. Selective estrogen receptor modulation in bone tissue
D. Intermittent administration of parathyroid hormone (PTH) analog that stimulates
osteoblastic activity and bone formation
CORRECT ANSWER: D. Intermittent administration of parathyroid hormone
(PTH) analog that stimulates osteoblastic activity and bone formation
Rationale: Teriparatide is a recombinant human parathyroid hormone (PTH 1-34). In
contrast to continuous PTH elevation (which causes bone resorption), intermittent
administration paradoxically stimulates osteoblasts, increasing bone mineral density and
improving bone microarchitecture. It is the only anabolic agent for osteoporosis,
promoting new bone formation rather than just preventing resorption.
Question 4: A patient on long-term, high-dose glucocorticoid therapy is
prescribed a bisphosphonate for osteoporosis prevention. What is the primary
mechanism by which bisphosphonates exert their anti-resorptive effects?
A. Stimulation of osteoblast differentiation through the Wnt/β-catenin pathway
B. Binding to hydroxyapatite and inducing osteoclast apoptosis via inhibition of farnesyl
pyrophosphate synthase
C. Direct antagonism of parathyroid hormone receptors on osteoclasts
D. Conversion to active metabolites that inhibit osteocyte apoptosis
CORRECT ANSWER: B. Binding to hydroxyapatite and inducing osteoclast
apoptosis via inhibition of farnesyl pyrophosphate synthase
Rationale: Bisphosphonates are pyrophosphate analogs that bind avidly to bone mineral
(hydroxyapatite). They are internalized by osteoclasts during bone resorption. Once
inside, they inhibit farnesyl pyrophosphate synthase, an enzyme in the mevalonate
pathway. This prevents the prenylation of essential proteins, leading to osteoclast
dysfunction and apoptosis, thereby reducing bone resorption.
Question 5: Which of the following characteristics is a significant advantage of
the third-generation antiseizure medication lacosamide compared to
traditional sodium channel blockers?
,A. It has a significantly longer half-life allowing for once-weekly dosing
B. It acts by a novel mechanism that does not involve the sodium channel, making it
effective against all seizure types
C. It has a selective and slow inactivation of voltage-gated sodium channels with
minimal effect on fast inactivation, potentially leading to a better side-effect profile
D. It is exclusively metabolized by the kidneys, making it safe in all patients with hepatic
impairment
CORRECT ANSWER: C. It has a selective and slow inactivation of voltage-gated
sodium channels with minimal effect on fast inactivation, potentially leading
to a better side-effect profile
Rationale: Lacosamide enhances the slow inactivation of voltage-gated sodium
channels, with little to no effect on the fast inactivation process. This is in contrast to
drugs like phenytoin or carbamazepine, which primarily affect fast inactivation. The
selective action on slow inactivation is thought to be responsible for its efficacy and a
potentially more favorable central nervous system side-effect profile, such as less
cognitive impairment.
Question 6: A patient with a history of gout is prescribed hydrochlorothiazide
for hypertension. The patient's serum uric acid level increases. This adverse
effect is primarily due to which action of thiazide diuretics?
A. Increased urate reabsorption in the proximal convoluted tubule
B. Competitive inhibition of urate secretion by the organic anion transporter (OAT) in the
proximal tubule
C. Inhibition of uric acid synthesis by xanthine oxidase
D. Enhanced degradation of purines leading to increased uric acid production
CORRECT ANSWER: B. Competitive inhibition of urate secretion by the organic
anion transporter (OAT) in the proximal tubule
Rationale: Thiazide diuretics decrease the excretion of uric acid. They are weak organic
acids that compete with urate for secretion via the organic anion transporter (OAT) in
the proximal convoluted tubule. This reduces uric acid clearance, leading to elevated
serum uric acid levels and potentially precipitating gout in susceptible patients.
Question 7: A 52-year-old female is started on anastrozole for estrogen
receptor-positive breast cancer. What is the precise pharmacologic target and
effect of this medication?
A. Irreversible inhibition of the estrogen receptor on breast tissue
B. Competitive inhibition of 17β-hydroxysteroid dehydrogenase
C. Selective antagonism of the progesterone receptor
D. Reversible inhibition of the aromatase enzyme, decreasing peripheral conversion of
androgens to estrogens
CORRECT ANSWER: D. Reversible inhibition of the aromatase enzyme,
decreasing peripheral conversion of androgens to estrogens
, Rationale: Anastrozole is a non-steroidal aromatase inhibitor. Aromatase is the enzyme
responsible for the conversion of androstenedione and testosterone to estrone and
estradiol, respectively. By reversibly inhibiting this enzyme, it reduces circulating
estrogen levels, a key driver for hormone-responsive breast cancer growth in
postmenopausal women.
Question 8: A patient with severe peptic ulcer disease related to NSAID use is
prescribed misoprostol. Which of the following is the most critical
contraindication to this medication, and what is the primary mechanism for its
gastroprotective effect?
A. Pregnancy; it stimulates uterine contractions and increases gastric mucus and
bicarbonate secretion
B. Asthma; it inhibits prostaglandin synthesis
C. Renal failure; it causes significant sodium retention
D. Hypertension; it acts as a potent vasoconstrictor
CORRECT ANSWER: A. Pregnancy; it stimulates uterine contractions and
increases gastric mucus and bicarbonate secretion
Rationale: Misoprostol is a synthetic prostaglandin E1 analog. Its primary mechanism of
gastroprotection is stimulating the production of gastric mucus and bicarbonate, thereby
enhancing the mucosal barrier. It also reduces acid secretion. Misoprostol is absolutely
contraindicated in pregnancy because it is a potent abortifacient and can cause uterine
contractions and cervical ripening.
Question 9: A 48-year-old male with bipolar disorder is started on lithium.
Which of the following is the primary and most widely accepted mechanism of
action for lithium's mood-stabilizing effects?
A. Blockade of dopamine D2 receptors in the mesolimbic pathway
B. Enhancement of GABA-A receptor activity throughout the central nervous system
C. Inhibition of the sodium-potassium-ATPase pump and alteration of neurotransmitter
reuptake
D. Inhibition of inositol monophosphatase, leading to depletion of inositol and disruption
of the phosphatidylinositol second messenger system
CORRECT ANSWER: D. Inhibition of inositol monophosphatase, leading to
depletion of inositol and disruption of the phosphatidylinositol second
messenger system
Rationale: While the exact mechanism of lithium is not fully understood, a prominent
theory involves its inhibition of inositol monophosphatase. This enzyme is crucial for the
recycling of inositol in the phosphatidylinositol (PI) cycle. Inhibition leads to a depletion
of inositol, which disrupts the signaling pathways that depend on this second messenger
system, particularly in neurons. This is thought to affect intracellular signaling pathways
that modulate mood.
